Epizyme Inc. (Nasdaq: EPZM) reported upbeat interim data from a Phase 2 clinical trial of tazemetostat. Shares of the biopharmaceutical climbed $1.20 to close at $12.35.
Epizyme reports positive interim data
June 14, 2017 at 18:27 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.